There is a growing recognition of sex-related disparities in atrial fibrillation (AF). However, limited data is available in Chinese AF patients.
Background
Atrial fibrillation (AF), the most common arrhythmia, affected more than 33 million individuals in 2010 worldwide. It increases the burden of stroke, heart failure, cognitive decline, and mortality [1, 2] . Sex-related disparities in AF are increasingly acknowledged [3] [4] [5] . Western countries have reported that clinical presentations and quality of life (QoL) differed between women and men with AF [6] [7] [8] , and women with AF seemed to be under-treated compared to men [8] [9] [10] . However, sex differences are not well-examined in Chinese AF patients.
The China AF Registry study is an ongoing prospective registry -one of the largest for Asian AF patients. It will provide an excellent opportunity to evaluate this knowledge gap. A better understanding of the sex differences in AF may have important implications for quality improvement to reduce or even eliminate the sex disparities in AF care.
In this study, we used data from the China AF Registry to evaluate sex-related differences with the presentation, QoL, and treatment in Chinese AF patients.
Material and Methods
The China AF Registry study is a prospective, multicenter, ongoing registry study of AF patients from 31 hospitals in Beijing, China. The design of the study had been published [11] . Local ethics committee approval was obtained and all participants provided signed informed consent.
Study population
The China AF Registry study had enrolled 19 515 AF patients from August 2011 to December 2016. In this analysis, we excluded 546 patients with mitral stenosis or valvular surgery, 3380 patients without valid Atrial Fibrillation Effects on QualiTy of Life (AFEQT) questionnaires, and 866 patients without European Heart Rhythm Association (EHRA) classification data. Finally, we included 14 723 participants. Figure 1 shows a flowchart of the study.
Data collection
Clinicians in participating hospitals collected data from medical charts. Collecting information included necessary socio-demographic data, AF type and duration, medical history, symptom and AFEQT questionnaires, and previous and current treatment. We defined variables according to the ACC/AHA recommendations on AF clinical data standards [12] .
AF symptoms and QoL evaluation
AF-related symptoms were evaluated using the EHRA AF symptom classification: no symptoms (EHRA I), mild symptoms (EHRA II), severe symptoms (EHRA III), and disabling symptoms (EHRA IV) [13] .
A Chinese version of the AFEQT questionnaire was collected to assess health-related quality of life (HRQoL) at baseline. The AFEQT questionnaire is an AF-specific QoL evaluation which was recently developed and validated, supporting its use as a self-administered outcome measure in studies and as a tool for disease management [14] . The AFEQT questionnaire contains 20 questions to evaluate the influence of AF on patients' HRQoL during the past 4 weeks. The 18 items generate 3 individual subscales -Symptoms, Daily Activities, and Treatment Concern. The last 2 indicate the Treatment Satisfaction domain. Overall AFEQT score is calculated based on the first 3 functional subscales. To be valid, the AFEQT questionnaires must have should at least half of the questions answered for each domain. AFEQT is scored with a 7-point Likert scale. The range of overall AFEQT or subscale scores is 0-100. Score 0 represents extremely disability and 100 indicates not at all limited. Thus, higher ratings indicate a better health status. For a percentage grading system of AFEQT scores, we set ³60 as passing scores indicating a 'normal level' of QoL, and the lower score sections as mild impairment of QoL (AFEQT scores 40-59), moderate impairment of QoL (AFEQT scores 20-39) and severe impairment of QoL (AFEQT <20).
Statistical analysis
Continuous variables showed a mean±standard deviation or median (interquartile range); differences were assessed using the t test or Wilcoxon rank-sum test. Categorical variables are 19 shown as numbers (percentages), and differences were compared using the chi-square test.
Multivariate logistic regression analysis was performed to assess the association between sex and QoL (the proportion of overall AFEQT score ³60). We corrected variables with potential influence on QoL, including age, body mass index (BMI), medical insurance and education, smoking, comorbidities (heart failure, hypertension, diabetes, previous thromboembolism, vascular disease, hyperlipidemia, and renal dysfunction), AF type and duration, and current pharmacological treatments.
A two-tailed P value <0.05 was considered statistically significant. We used SAS software 9.2 for data analyses.
Results
Among 14 723 patients with AF included in this study, 5645 (38.3%) were women. Table 1 shows the characteristics of the patients. Since women were older on average by 5 years than men in the study (67.5±10.6 vs. 62.2±12.2, P<0.0001), we stratified the patients by age<75 and age ³75 groups. In both age groups, women had higher rates of heart failure, hypertension, diabetes, and renal dysfunction, but a lower rate of vascular disease. Previous thromboembolism was similar according to sex in both 2 age groups. Paroxysmal AF (65.3% vs. 55.8%, P<0.0001) and a CHA 2 DS 2 -VAS C score ³2 (82.2% vs. 45.3%, P<0.0001) was more prevalent in women for those aged <75 years.
AF-related symptoms
Female AF patients experienced more severe or disabling symptoms, with a higher proportion of EHRA III and IV classification, than men (35.6% vs. 24.0%, P<0.0001). Only 5.4% of women had no symptom, compared with 8.4% of men ( Figure 2 ). Both age groups had similar results. (Figure 3 ). We also compared the mean value of overall AFEQT and each subscale score by sex, type of AF, and CHA 2 DS 2 -VASc scores, as shown in Figure 4 . Women had lower overall AFEQT scores than men in those aged <75 years (59.6±15.0 vs. 64.4±14.2, P<0.0001) and in older groups (57.5±15.1 vs. 61.2±15.3, P<0.0001). In newly diagnosed, paroxysmal AF, or persistent AF, women had lower overall AFEQT scores than men (All P <0.05 except for newly diagnosed AF in age ≥75 years group). Also, the AFEQT scores decreased in women across all CHA 2 DS 2 -VASc score groups. After the correction of demographics, comorbidities, and pharmacological treatments, female sex remained independently associated with lower overall AFEQT score (OR 0.69; 95%CI, 0.63-0.76; P<0.0001).
Quality of life

AF-related treatment
We found no sex disparity in the prior use of electrical cardioversion ( 
Discussion
This massive Chinese AF cohort study indicated that women with AF tended to be older, with more comorbidities and 8014 more severe symptoms. After adjustment, women had lower QoL than men. Moreover, despite being much more likely to be symptomatic, women tended to receive less rhythm-control treatment in those aged <75. OAC use was low and had no sex difference in high stroke risk AF patients.
Prior extensive cohort studies have shown sex disparities in clinical features, treatment, and outcomes of AF in Western countries [6, 7] . Female AF patients tended to be older, and were more likely to have a high burden of hypertension and heart failure with a preserved ejection fraction [15] . However, few studies have reported the association between sex and symptoms burden and QoL [8, 16, 17] . In a European survey, the EORP-AF study, women were found to have more symptoms, including palpitations, fear, and anxiety [7] . A systematic review suggested that asymptomatic AF was less common among women than among men [18] . A Europe survey reported that women had a lower general QoL using EuroQol scores [8] . The ORBIT-AF registry [6] , a US-based observational study, has demonstrated that female AF patients had more significant impairment of HRQoL as measured by specific AFEQT scores. Such sex differences were consistent with our large cohort study of Chinese AF patients, and a recently published systemic review has confirmed this [19] . The physical and psychosomatic characteristics of female patients may be related to the observed differences in clinical characteristics and presentation [20] [21] [22] [23] [24] . Older age may also contribute to the differences in comorbidities, since women were older by an average of 5 years compared with men [20] . However, the differences in QoL were still significant after multivariable adjustment.
Guidelines indicate rhythm-control therapy to improve the symptom of AF patients (Class I, level B) [25] . In our study, younger (age <75) female AF patients were treated more conservatively with less catheter ablation or antiarrhythmic drugs than men, despite having a higher proportion of paroxysmal AF, more severe AF-related symptoms, and worse QoL. The ORBIT-AF study did not find sex-specific differences in the use of antiarrhythmic drugs [6] , but women tended to receive less electric cardioversion or ablation therapy. The EORP-AF study reported similar differences in treatment [7] . Women with symptomatic AF received less rhythm-control treatment, and we observed the same treatment pattern in asymptomatic patients.
Nevertheless, these studies did not adjust for some critical factors, including age, comorbidities, duration, and symptom burden of AF. The reasons for the disparities remain mostly unknown, and potential explanations include sex differences in patient preferences and other clinical and socioeconomic factors [26] . Age may play an essential role in treatment strategy referral [15] . In our study, there was no sex-specific difference in rhythm-control treatment for patients ³75 years. The efficacy and safety of antiarrhythmic drugs for women may influence the treatment preferences [27] [28] [29] . In addition, women tended to be less educated and less covered by health insurance than men in our study. Thus, they may be more likely to delay seeking medical care and to accept more conservative treatment than men.
Our study observed that OAC for preventing stroke in high-risk patients was substantially underused regardless of sex, and women received OAC use similarly to men. Previous substantial worldwide cohort research reported no sex differences in the use of OAC [30, 31] . The EORP-AF and ORBIT-AF study found similar results [6, 7] . However, in another outpatient AF cohort, with a CHA 2 DS 2 -VASc score ³2, women were associated with less frequent prescription of OAC [32] . Although the previous research suggested that female sex is not an independent risk factor of thromboembolism [33] , women had poorer long-term outcomes among stroke survivors [34, 35] . The extensive treatment gap in OAC use for stroke prevention remains in Chinese AF patients of both sexes. Therefore, great efforts are warranted to promote OAC therapy among highrisk patients with AF in China. 
Limitations
Conclusions
In this prospective Chinese Registry, women with AF tended to be older, with more comorbidities, and had more severe symptoms and poorer QoL, compared to men. Despite all these factors, women tended to receive less rhythm-control treatment than men in those aged <75 years. OAC was substantially underused in high stroke risk patients regardless of sex. 
